J. Knoll

发表

Cross-tolerance between para-bromo-methamphetamine (V-111) and LSD-25.

E. Vizi, J. Knoll, 1970, Pharmacology.

Anorectic Agents and Satietin, an Endogenous Inhibitor of Food Intake

J. Knoll, 1982 .

The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine

E. Vizi, J. Knoll, J. Knoll, 1976, Neuroscience.

Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.

N. Sato, K. Hayashi, S. Shimazu, 2003, Life sciences.

[Medicamentous strategy for improving the quality of life in the senescence].

J. Knoll, 1986, Wiener medizinische Wochenschrift. Supplement.

Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl.

J. Knoll, T. T. Yen, J. Dalló, 1989, Life sciences.

The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl

J. Knoll, 1988, Mechanisms of Ageing and Development.

Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.

J. Tímar, J. Knoll, B. Knoll, 1986, Archives internationales de pharmacodynamie et de therapie.

The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.

J. Knoll, 1993, Journal of neural transmission. Supplementum.

The facilitation of dopaminergic activity in the aged brain by (−)deprenyl. A proposal for a strategy to improve the quality of life in senescence

J. Knoll, 1985, Mechanisms of Ageing and Development.

A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor‐manifestation‐suppressing regulation in rat brain

P. Ferdinandy, L. Hársing, P. Hauser, 2017, Life sciences.

Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).

J. Knoll, I. Miklya, Jozsef Knoll, 2016, Life sciences.

Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L.) and (-)deprenyl.

J. Knoll, T. T. Yen, 1992, Acta physiologica Hungarica.

The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.

J. Knoll, 1992, Pharmacology & toxicology.

Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference.

J. Knoll, I. Miklya, T. T. Yen, 1994, Life sciences.

Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.

J. Knoll, 1990, Advances in neurology.

Interaction between phenylalkylamine derivatives and reserpine.

E. Vizi, J. Knoll, B. Knoll, 1968, International journal of neuropharmacology.

Satietin: A highly potent anorexogenic substance in human serum

J. Knoll, 1979, Physiology & Behavior.

The influence of naloxone on barbiturate anesthesia and toxicity in the rat.

F. Foldes, Z. Fürst, J. Knoll, 1977, Life sciences.

Neuronal peptide (enkephalin) receptors in the ear artery of the rabbit.

J. Knoll, 1976, European journal of pharmacology.

Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum

J. Knoll, I. Miklya, L. Harsing, 2022, International journal of molecular sciences.

Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

J. Knoll, Z. Ecseri, K. Kelemen, 1965, Archives internationales de pharmacodynamie et de therapie.

Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

J. Knoll, 2006, CNS drug reviews.

Some behavioural effects of (-) and (+)deprenyl and amphetamine enantiomers: A comparative study

J. Tímar, J. Knoll, B. Knoll, 1992 .

Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250).

E. Vizi, K. Magyar, J. Knoll, 1967, Acta physiologica Academiae Scientiarum Hungaricae.

Chromatographic studies on the binding, action and metabolism of (-)-deprenyl.

H. Kalasz, L. Kerecsen, J. Pucsok, 1990, Journal of chromatography.

Gas chromatographic studies of derivatives of celluline-like substances.

J. Nagy, J. Knoll, E. Tomori, 1974, Journal of chromatography.

Repeated administration of (-)deprenyl leaves the mesolimbic dopaminergic activity unchanged.

L. Hársing, K. Tekes, J. Knoll, 1990, Acta physiologica Hungarica.

Enhancer Regulation/Endogenous and Synthetic Enhancer Compounds: A Neurochemical Concept of the Innate and Acquired Drives

J. Knoll, 2003, Neurochemical Research.

Increase by enkephalin of acetylcholine release from striatal slices of the rat.

E. Vizi, L. Hársing, J. Knoll, 1978, Polish journal of pharmacology and pharmacy.

Further proof that (−) deprenyl fails to facilitate mesolimbic dopaminergic activity

K. Tekes, J. Tímar, Z. Gyarmati, 1993, Pharmacology Biochemistry and Behavior.

Direct evidence that eseroline possesses morphine-like effects.

G. Somogyi, A. Bartolini, A. Galli, 1982, European journal of pharmacology.

Selective inhibition of the "B form" of monoamine oxidase.

K. Magyar, J. Knoll, 1977, Polish journal of pharmacology and pharmacy.

THE DISCOVERY OF THE ENHANCER REGULATION IN THE MAMMALIAN BRAIN AND THE DEVELOPMENT OF THE SYNTHETIC ENHANCER SUBSTANCES A chance to significantly improve the quality and prolong the duration of human life

J. Knoll, 2016 .

Specific desensitition to PGE1 and PGE2 in guinea-pig ileum; evidence for a common receptor site.

P. Illés, J. Knoll, 1975, Pharmacological research communications.

Analysis of the Pharmacological Effects of Selective Monoamine Oxidase Inhibitors

J. Knoll, 2008 .

Effect of duration and frequency of stimulation on the presynaptic inhibition by α-adrenoceptor stimulation of the adrenergic transmission

E. Vizi, G. Somogyi, P. Hadházy, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Acetylcholine release from isolated vas deferens of the rat

E. Vizi, P. Illés, G. Somogyi, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

The effect of number of stimuli and rate of stimulation on the inhibition by PGE1 of adrenergic transmission.

E. S. Vizi, P. Illés, P. Hadházy, 1973, European journal of pharmacology.

Endogenous anorectic agents--satietins.

J. Knoll, Joseph Knoll, 1988, Annual review of pharmacology and toxicology.

A new model for the study of opiate B-receptors: isolated splenic strip of the cat.

L. Kerecsen, J. Knoll, 1981, Pharmacology.

A NEW MODEL FOR THE STUDY OF OPIATE B RECEPTORS: ISOLATED SPLENIC STRIPS OF THE CAT

L. Kerecsen, J. Knoll, 1980 .

Effect of prostaglandin E1 and indomethacin on responses of longitudinal muscle of guinea-pig ileum to cholecystokinin.

J. Knoll, S. Vizi, T. Török, 1979, European journal of pharmacology.

The anorectic effect of satietin is unrelated to carbohydrate metabolism

J. Knoll, L. Koranyi, J. Földes, 1985, Physiology & Behavior.

The effect of PGE2 on contraction delay and velocity of the field stimulated guinea-pig vas deferens

P. Illés, J. Knoll, Z. Torma, 1975, Neuropharmacology.

Metabolism of (-)deprenyl and its structural analogues

K. Magyar, É. Szökő, H. Kalasz, 1988 .

MONOAMINE OXIDASE AND ITS INHIBITION

J. Knoll, 1976 .

Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.

J. Knoll, 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(–)Deprenyl‐Medication: A Strategy To Modulate the Age‐Related Decline of the Striatal Dopaminergic System

J. Knoll, 1992, Journal of the American Geriatrics Society.

Responses of forebrain neurons to the MAO-B blocker l-deprenyl

I. Vida, Z. Karádi, B. Faludi, 1995, Brain Research Bulletin.

Pharmacological basis of the therapeutic effect of (−)deprenyl in age‐related neurological diseases

J. Knoll, 1992, Medicinal research reviews.

Critical role of MAO inhibition in Parkinson's disease.

J. Knoll, 1987, Advances in neurology.

Central nervous system stimulants and anorectic agents

J. Knoll, K. Kelemen, 1987 .

Satietin, a blood-borne anorectic glycoprotein, as the putative rate-limiting satiety signal in the negative feed-back of food intake

J. Knoll, 1984, Zeitschrift fur Ernahrungswissenschaft.

Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer.

T. Ishida, T. Yasusa, F. Yoneda, 2001, Bioorganic & Medicinal Chemistry.

1,6-Dimethyl-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrido(1,2-a)- pyrimidine-3-carboxamide (Ch-127) protects against the intestinal damage in rats caused by two weeks' daily administration of indomethacin.

I. Hermecz, K. Gyires, J. Knoll, 1987, Drugs under experimental and clinical research.

The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain

K. Magyar, J. Lengyel, J. Knoll, 2002, European Journal of Drug Metabolism and Pharmacokinetics.

Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

J. Knoll, I. Miklya, Jozsef Knoll, 2003, Life sciences.

Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP.

J. Knoll, I. Miklya, B. Knoll, 2002, Life sciences.

1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.

S. Shimazu, T. Yasusa, F. Yoneda, 2002, Life sciences.

(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.

J. Knoll, Jozsef Knoll, 1998, Pharmacology & toxicology.

Sexual performance and longevity

J. Knoll, 1997, Experimental Gerontology.

Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.

J. Knoll, I. Miklya, 1995, Life sciences.

Memories of my 45 years in research.

J. Knoll, 1994, Pharmacology & toxicology.

Predictive values of pharmacological models to study opiate dependence

J. Knoll, 1975, Neuropharmacology.

Azidomorphine and rymazolium an approach to the ideal analgesic

J. Knoll, 1973 .

[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].

J. Knoll, 1997, Voprosy meditsinskoi khimii.

Evidence that acetylcholine released by gastrin and related polypeptides contributes to their effect on gastrointestinal motility.

M. Impicciatore, G. Bertaccini, J. Knoll, 1973, Gastroenterology.

Inhibition of the effects of LSD and p-bromo-methamphetamine (V-111) by p-chlorophenylalanine

E. Vizi, J. Knoll, 1970 .

Effect of hemicholinium-3 on the release and net synthesis of acetylcholine in Auerbach's plexus of guinea pig ileum

E. Vizi, G. Somogyi, J. Knoll, 1977, Neuroscience.

Long-lasting, true aphrodisiac effect of (-)-deprenyl in sexually sluggish old male rats.

J. Knoll, J. Dalló, T. Yen, 1983, Modern problems of pharmacopsychiatry.

Acetylcholine-releasing effect of gastrin and related polypeptides.

E. Vizi, M. Impicciatore, G. Bertaccini, 1972, European journal of pharmacology.

Effect of lithium on acetylcholine release and synthesis.

E. Vizi, P. Illés, J. Knoll, 1972, Neuropharmacology.

The effects of sympathetic nerve stimulation and guanethidine on parasympathetic neuroeffector transmission; the inhibition of acetylcholine release

E. Vizi, J. Knoll, 1971, The Journal of pharmacy and pharmacology.

Effect of frequency of stimulation on the inhibition by noradrenaline of the acetylcholine output from parasympathetic nerve terminals

E. Vizi, J. Knoll, 1971, British journal of pharmacology.

The possible mechanisms of action of (-)deprenyl in Parkinson's disease

J. Knoll, Joseph Knoll, 2005, Journal of Neural Transmission.

The pharmacology of azidomorphine and azidocodeine

S. Fûrst, J. Knoll, K. Kelemen, 1973, The Journal of pharmacy and pharmacology.

(-)Deprenyl (Selegiline): past, present and future.

J. Knoll, 2000, Neurobiology.

(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

F. Yoneda, J. Knoll, I. Miklya, 1999, British journal of pharmacology.

Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action.

K. Magyar, J. Knoll, J. Knoll, 1978, Biochemical pharmacology.

(-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.

M. Barbaccia, E. Costa, G. Zsilla, 1983, European journal of pharmacology.

The regular occurrence of thick filaments in stretched mammalian smooth muscle.

E. Vizi, J. Knoll, N. Garamvölgyi, 1971, Journal of ultrastructure research.

The analysis of post-tetanic potentiation in guinea-pig ileum longitudinal muscle strip.

G. Somogyi, K. Mašek, O. Kadlec, 1982, European Journal of Pharmacology.

RELATIONSHIPS BETWEEN THE SUGGESTED OPIOID RECEPTORS

T. Friedmann, J. Knoll, 1986 .

Opiate and dopamine receptors in the isolated nictitating membrane of the cat.

P. Illés, J. Knoll, 1978, Polish journal of pharmacology and pharmacy.

The Isolated Nictitating Membrane of the Cat

P. Illés, J. Knoll, 1978 .

Structure-activity relationship of some analogues of gastrin and cholecystokinin on intestinal smooth muscle of the guinea-pig

E. Vizi, P. Mantovani, G. Bertaccini, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Presynaptic Modulation by Norepinephrine and Dopamine of Acetylcholine Release in the Peripheral and Central Nervous System

E. Vizi, L. Hársing, J. Knoll, 1978 .

Inhibitory effects of prostaglandin E1 on responses of rabbit ear artery to nerve stimulation and on release of norepinephrine.

E. Vizi, K. Magyar, P. Hadházy, 1976, Advances in prostaglandin and thromboxane research.

Presynaptic inhibition leading to disinhibition of acetylcholine release from interneurons of the caudate nucleus: Effects of dopamine, β-endorphin and d-Ala2-Pro5-enkephalinamide

E. Vizi, L. Hársing, J. Knoll, 1977, Neuroscience.

Presynaptic inhibition of acetylcholine release by endogenous and exogenous noradrenaline at high rate of stimulation.

E. Vizi, J. Knoll, 1970, British journal of pharmacology.

The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine.

J. Knoll, A. Abdorubo, 1988, Polish journal of pharmacology and pharmacy.

Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.

J. Knoll, D. Rácz, I. Miklya, 1996, Life sciences.

Possible mechanism of the low tolerance capacity of azidomorphine and azidocodeine.

G. Zsilla, J. Knoll, 1974, Biochemical pharmacology.

Inhibition of adrenergic neurotransmission by prostaglandin E1 (PGE1) in the rabbit ear artery

E. Vizi, K. Magyar, P. Hadházy, 1976, Neuropharmacology.

Sixth Meeting of the ‘Italian League against Parkinson’s Disease and Extrapyramidal Disorders’

R. M. Threatte, M. Fregly, J. Fischer, 1981 .

[Effect of parasympathomimetics on analgesia].

J. Pórszász, J. Knoll, E. Komlós, 1951, Acta physiologica Academiae Scientiarum Hungaricae.

L-deprenyl plus l-phenylalanine in the treatment of depression

P. Riederer, W. Birkmayer, J. Knoll, 2005, Journal of neural transmission.

How Selegiline ((-)-Deprenyl) Slows Brain Aging

J. Knoll, 2012 .

Some puzzling pharmacological effects of monoamine oxidase inhibitors.

K. Magyar, J. Knoll, J. Knoll, 1972, Advances in biochemical psychopharmacology.

Interaction of selective inhibitors of monoamine oxidase with pethidine in rabbits.

M. Mattila, J. Knoll, A. Jounela, 1977, Biochemical pharmacology.

The pharmacology of selegiline ((−)deprenyl). New aspects

J. Knoll, 1989, Acta neurologica Scandinavica. Supplementum.

Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

P. Riederer, W. Birkmayer, M. Youdim, 1985, Journal of Neural Transmission.

Deprenyl (selegiline): the history of its development and pharmacological action

J. Knoll, Joseph Knoll, 1983, Acta neurologica Scandinavica. Supplementum.

Pharmacological evidence that the anxiolytic effect of tofisopam is related to a subgroup of benzodiazepine receptors

J. Knoll, D. Rácz, I. Miklya, 1988 .

[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].

G. Menke, J. Knoll, N. Rietbrock, 2008, Deutsche medizinische Wochenschrift.

The L-DOPA-sparing effect of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in reserpine-pretreated rats.

S. Shimazu, F. Yoneda, J. Knoll, 2003, Life sciences.

The EEG arousal reaction in rats with extinguishable and non-extinguishable conditioned reflexes

D. Bovet, V. Longo, J. Knoll, 1961 .

Motimeter, a new sensitive apparatus for the quantitative measurement of hypermotility caused by psychostimulants.

J. Knoll, 1961, Archives internationales de pharmacodynamie et de therapie.

Satietin; a 50,000 dalton glycoprotein in human serum with potent, long-lasting and selective anorectic activity

J. Knoll, 2005, Journal of Neural Transmission.

Satietins, α1‐glycoproteins in human plasma with potent, long‐lasting and selective anorectic activity

J. Knoll, 1987, Medicinal research reviews.

Recycling gel chromatography of phenolic compounds. II. Numerical calculation of optimal number of cycles and resolution

H. Kalasz, J. Nagy, J. Knoll, 1975 .

Experimental analysis of the central effect of convulsive hydrazides.

J. Knoll, K. Kelemen, J. Nievel, 1961, Acta physiologica Academiae Scientiarum Hungaricae.

Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response

K. Baghy, J. Tímar, D. Zelena, 2020, Behavioural Brain Research.

The Brain and Its Self: A Neurochemical Concept of the Innate and Acquired Drives

J. Knoll, 2005 .

A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.

J. Knoll, I. Miklya, B. Knoll, 2003, Life sciences.

Sexual hormones terminate in the rat: the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period.

J. Knoll, I. Miklya, B. Knoll, 2000, Life sciences.

Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.

J. Knoll, I. Miklya, Jozsef Knoll, 1994, Archives internationales de pharmacodynamie et de therapie.

(−)Deprenyl and (−)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin

J. Sugar, V. Tóth, M. Kummert, 1992, Mechanisms of Ageing and Development.

The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.

S. Yasar, J. Tímar, J. Knoll, 1992, Archives internationales de pharmacodynamie et de therapie.

R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.

J. Knoll, J. Knoll, 1987, Journal of neural transmission. Supplementum.

Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition.

E. Vizi, L. Hársing, K. Magyar, 1979, Polish journal of pharmacology and pharmacy.

The theory of active reflexes : an analysis of some fundamental mechanisms of higher nervous activity

J. Knoll, 1969 .

The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine.

J. Knoll, N. Lekka, J. Dalló, 1986, Polish journal of pharmacology and pharmacy.

MODULATION OF NEUROTRANSMITTER RECEPTORS AND DRUG RECOGNITION SITES BY REPEATED DOSES OF (-)DEPRENYL

A. Székely, G. Zsilla, J. Knoll, 1986 .

SENSITIVITY OF OPIATE RECEPTORS IN WITHDRAWAL SYNDROME

E. Vizi, J. Knoll, G. Hársing, 1980 .

Azidomorphines: a new family of potent analgesics with low dependence capacity.

J. Knoll, 1979, Progress in neuro-psychopharmacology.

The pharmacology of 14‐hydroxyazidomorphine

J. Knoll, S. Fürst, S. Makleit, 1975, The Journal of pharmacy and pharmacology.

Pharmacology of azidomorphine

V. M. Bulaev, V. V. Zakusov, J. Knoll, 1978, Bulletin of Experimental Biology and Medicine.

OPIATE-A RECEPTORS RELATE TO CHOLINERGIC AND OPIATE-B RECEPTORS TO CATECHOLAMINERGIC NEURONS

J. Knoll, 1980 .

Kinetic parameters of a new narcotic agonist, azidomorphine.

E. Vizi, J. Knoll, S. Fürst, 1973, Pharmacology.

Two kinds of opiate receptor.

J. Knoll, 1977, Polish journal of pharmacology and pharmacy.

The pharmacology of N-substituted azidomorphines.

J. Knoll, S. Fürst, S. Makleit, 1977, Archives internationales de pharmacodynamie et de therapie.

Azidomorphines and homopyrimidazols: a new approach to the ideal analgetic.

J. Knoll, 1977, Acta physiologica et pharmacologica Bulgarica.

Symposium on Analgesics

E. Vizi, J. Knoll, 1976 .

The metabolism of azidomorphine in the rat.

G. Zsilla, J. Knoll, S. Makleit, 1975, Medical biology.

Absorption, distribution and elimination of azidomorphine and related substances.

K. Magyar, J. Knoll, G. Zólyomi, 1975, Acta physiologica Academiae Scientiarum Hungaricae.

Circulatory, respiratory and antitussive effects of azidomorphine and related substances.

L. Hársing, P. Hadházy, T. Friedmann, 1974, Archives internationales de pharmacodynamie et de therapie.

Effect of azidomorphine and related substances on the intestinal motility.

E. Vizi, J. Knoll, J. Zséli, 1974, Pharmacology.

Synthesis of new analgetic homopyrimidazoles.

G. Horváth, I. Hermecz, Z. Meszaros, 1972, Arzneimittel-Forschung.

The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methylsulphate (MZ-144), a new, potent, non-narcotic analgesic. IV. The fate of MZ-144 within the organism.

K. Magyar, J. Knoll, D. Bánfi, 1971, Arzneimittel-Forschung.

The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methylsulphate (MZ-144), a new, potent, non narcotic analgesic. I. Some basic correlations between the chemical structure and activity of homopyrimidazol analgesics. Selection of MZ-144.

Z. Meszaros, J. Knoll, S. Fürst, 1971, Arzneimittel-Forschung.

The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydrohomopyrimidazol-methylsulphate (MZ-144), a new, potent, non-narcotic analgesic. II. Toxicity and analgetic effect of MZ-144 compared to narcotic and non-narcotic analgesics.

Z. Meszaros, J. Knoll, S. Fürst, 1971, Arzneimittel-Forschung.

Morphin-prostigmin synergismus.

J. Pórszász, J. Knoll, E. Komlós, 1950, Acta physiologica Academiae Scientiarum Hungaricae.

The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methylsulphate (MZ-144), a new, potent, non-narcotic analgesic. 3. Analysis of the central and peripheric effects.

Z. Meszaros, J. Knoll, S. Fürst, 1971, Arzneimittel-Forschung.

CHARACTERISTICS OF OPIATE A AND B RECEPTORS STIMULATED OR INHIBITED BY INTRATHECALLY ADMINISTERED OPIATES IN THE RAT

S. Fürst, J. Knoll, 1986 .

The role of metabolic factors in the interaction between opiates and homopyrimidazoles in the central nervous system

L. Hársing, K. Magyar, K. Tekes, 1980 .

(-)Deprenyl — the MAO inhibitor without the ‘cheese effect’

J. Knoll, 1979, Trends in Neurosciences.

Differentiation of multiple analgesic opiate receptors.

J. Knoll, S. Fürst, 1985, International journal of tissue reactions.

Quantitative studies of the antagonism by naloxone and N-cyclopropylmethyl-norazido-dihydroisomorphine (CAM) of different opiates.

J. Knoll, S. Fürst, 1982, Polish journal of pharmacology and pharmacy.

The pharmacology of (-)deprenyl.

J. Knoll, 1986, Journal of neural transmission. Supplementum.

A procedure for measuring neuromelanin in neurocytes by a TV-image analyser

J. Sugar, V. Tóth, M. Kummert, 1992, Mechanisms of Ageing and Development.

Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson’s Disease

J. Knoll, 1986 .

Effect of prostaglandin E1 on the cardiac transmembrane potentials.

V. Kecskeméti, J. Knoll, K. Kelemen, 1973, European journal of pharmacology.

Drugs affecting the calcium-dependent slow depolarization mechanism of the cardiac cell membrane.

V. Kecskeméti, J. Knoll, K. Kelemen, 1982, Advances in myocardiology.

Effect of prostacyclin on cardiac transmembrane currents.

V. Kecskeméti, J. Knoll, K. Kelemen, 1982, Advances in myocardiology.

EFFECT OF PRIMARY PROSTAGLANDINS AND PROSTACYCLIN ON CARDIAC TRANSMEMBRANE POTENTIALS

J. Knoll, K. Kelemen, Kecskeméti Valéria, 1980 .

Microelectrophysiological analysis of the cardiac effect of prostaglandin E2.

V. Kecskeméti, J. Knoll, K. Kelemen, 1974, Polish journal of pharmacology and pharmacy.

Dose-dependent effect of prostaglandins on cardiac transemenbrane potential.

V. Kecskeméti, J. Knoll, K. Kelemen, 1976, Acta biologica et medica Germanica.

Drugs affecting the tetrodotoxin-sensitive ("fast") sodium mechanism in the cardiac cell membrane.

V. Kecskeméti, J. Knoll, K. Kelemen, 1982, Advances in myocardiology.

Comparative effects of prostaglandin F2alpha and A2 on the cardiac transmembrane potentials.

V. Kecskeméti, J. Knoll, K. Kelemen, 1978, Acta biologica et medica Germanica.

COMPARATIVE EFFECT OF PROSTACYCLIN AND PRIMARY PROSTAGLANDINS ON CARDIAC TRANSMEMBRANE CURRENTS

V. Kecskeméti, J. Knoll, K. Kelemen, 1980 .

The effects of PGE1 on responses to cardiac vagus nerve stimulation and acetylcholine release.

P. Illés, P. Hadházy, J. Knoll, 1973, European journal of pharmacology.

Adrenergic neuroeffector junctions sensitive and insensitive to the effect of PGE.

E. Vizi, P. Illés, J. Knoll, 1974, Polish journal of pharmacology and pharmacy.

Opiate agonists inhibit noradrenaline release via opiate B-receptors and N-cyclopropylmethylnorazidomorphine (CAM) blocks electrically evoked contractions via histamine in the mouse vas deferens.

G. Somogyi, L. Kerecsen, J. Knoll, 1981, Archives internationales de pharmacodynamie et de therapie.

An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.

J. Knoll, I. Miklya, B. Knoll, 2003, Life sciences.

High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers.

J. Knoll, I. Miklya, B. Knoll, 1996, Life sciences.

(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.

P. Riederer, W. Birkmayer, M. Youdim, 1983, Modern problems of pharmacopsychiatry.

Satietin, a blood-borne, highly selective and potent anorectic glycoprotein.

J. Knoll, 1985, Biomedica biochimica acta.

The action of (-) deprenyl on monoamine turnover rate in rat brain.

G. Zsilla, J. Knoll, 1982, Advances in biochemical psychopharmacology.

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma

I. Kovalszky, K. Baghy, Z. Schaff, 2019, Pathology & Oncology Research.

Absorption, distribution and elimination of drotaverine.

M. Lengyel, K. Magyar, J. Knoll, 1978, Acta physiologica Academiae Scientiarum Hungaricae.

(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.

J. Knoll, I. Miklya, B. Knoll, 1996, Life sciences.

Inflammation and writhing syndrome inducing effect of PGE1, PGE2 and the inhibition of these actions.

K. Gyires, J. Knoll, 1975, Polish journal of pharmacology and pharmacy.

(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release.

A. Akaike, H. Katsuki, S. Shimazu, 2001, European Journal of Pharmacology.

Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

F. Yoneda, J. Knoll, I. Miklya, 2001, Bioorganic & medicinal chemistry.

The structure-action relationship and kinetics of some naloxone and naltrexone derivatives.

E. Vizi, F. Foldes, J. Knoll, 1976, Pharmacology.

Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

K. Magyar, J. Knoll, B. Ekstedt, 1979, Biochemical pharmacology.

Influence of repeated administration of (-)deprenyl on serotonin syndrome in rats

J. Tímar, J. Knoll, B. Knoll, 1988 .

SELECTIVE INHIBITORS OF MAO-B WITH DIFFERENT PHARMACOLOGICAL PROFILES

J. Knoll, 1980 .

STRUCTURE-ACTIVITY RELATIONSHIP OF SELECTIVE INHIBITORS OF MAO-B

K. Magyar, J. Knoll, Z. Ecseri, 1980 .

(-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.

J. Knoll, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Analgesic profile of rimazolium as compared to different classes of pain killers.

S. Fûrst, K. Gyires, J. Knoll, 1988, Arzneimittel-Forschung.

The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.

A. Székely, G. Zsilla, P. Földi, 1986, Polish journal of pharmacology and pharmacy.

The action of enkephalins and enkephalin analogues on neurotransmission in the isolated nictitating membrane of the cat

P. Illés, J. Knoll, K. Medzihradszky, 1978, The Journal of pharmacy and pharmacology.

THE SPECIFIC ACTIVATION OF THE CNS AND ITS SIGNIFICANCE IN PSYCHOPHARMACOLOGICAL RESEARCH

J. Knoll, 1965 .

The site and state of myosin in intestinal smooth muscle.

E. Vizi, J. Knoll, N. Garamvölgyi, 1973, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

DEPRENYL INHIBITS DOPAMINE UPTAKE IN THE RAT STRIATUM IN VIVO

E. Vizi, L. Hársing, K. Magyar, 1980 .